3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
February 2025 in “Diagnostics” Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
September 2022 in “Plastic and Reconstructive Surgery” Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
2 citations
,
February 2024 in “Indian Dermatology Online Journal” Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
1 citations
,
February 2021 in “Farmacja Polska” Janus kinase inhibitors show promise in treating autoimmune skin diseases.
7 citations
,
May 2025 in “Journal of Biomedical Science” Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
May 2018 in “White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)” Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
July 2023 in “Dermatology and therapy” People with alopecia areata may have a higher risk of blood clots.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
8 citations
,
November 2024 in “EMBO Molecular Medicine” Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
March 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Vitiligo treatment requires a personalized mix of therapies to restore skin color and improve life quality.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.